MX2011011928A - Procedimiento y composicion para mejorar la absorcion de agentes terapeuticos. - Google Patents
Procedimiento y composicion para mejorar la absorcion de agentes terapeuticos.Info
- Publication number
- MX2011011928A MX2011011928A MX2011011928A MX2011011928A MX2011011928A MX 2011011928 A MX2011011928 A MX 2011011928A MX 2011011928 A MX2011011928 A MX 2011011928A MX 2011011928 A MX2011011928 A MX 2011011928A MX 2011011928 A MX2011011928 A MX 2011011928A
- Authority
- MX
- Mexico
- Prior art keywords
- composition
- therapeutic agents
- improve absorption
- active ingredient
- tablet
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Un comprimido con un perfil de disolución potenciado para un ingrediente medicinalmente activo, tal como aspirina y procedimientos para fabricar el comprimido. El comprimido comprende una mezcla de cristales del ingrediente medicinalmente activo y un adyuvante de disolución, tal como carbonato o bicarbonato de sodio o calcio que recubre los cristales tras la molienda conjunta. La mezcla se comprime posteriormente para conformar comprimidos que tienen un perfil de disolución potenciado para el ingrediente medicinalmente activo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/387,977 US11135188B2 (en) | 2009-05-11 | 2009-05-11 | Method and composition to improve absorption of therapeutic agents |
PCT/US2010/001375 WO2010132095A1 (en) | 2009-05-11 | 2010-05-10 | Method and composition to improve absorption of therapeutic agents |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2011011928A true MX2011011928A (es) | 2011-12-06 |
Family
ID=43062708
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011011928A MX2011011928A (es) | 2009-05-11 | 2010-05-10 | Procedimiento y composicion para mejorar la absorcion de agentes terapeuticos. |
Country Status (15)
Country | Link |
---|---|
US (1) | US11135188B2 (es) |
EP (1) | EP2429502B1 (es) |
AR (1) | AR076864A1 (es) |
BR (1) | BRPI1013509A2 (es) |
CA (1) | CA2761678A1 (es) |
CL (1) | CL2011002807A1 (es) |
CO (1) | CO6460753A2 (es) |
EA (1) | EA201171399A1 (es) |
HU (1) | HUE043173T2 (es) |
MX (1) | MX2011011928A (es) |
PL (1) | PL2429502T3 (es) |
PT (1) | PT2429502T (es) |
SI (1) | SI2429502T1 (es) |
UY (1) | UY32624A (es) |
WO (1) | WO2010132095A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11135188B2 (en) | 2009-05-11 | 2021-10-05 | Bayer Healthcare Llc | Method and composition to improve absorption of therapeutic agents |
HUE047749T2 (hu) * | 2013-02-06 | 2020-05-28 | Hermes Arzneimittel Gmbh | Gyógyszereket alacsony dózisban tartalmazó gyógyászati készítmények |
CA2919892C (en) | 2013-08-12 | 2019-06-18 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded immediate release abuse deterrent pill |
US9492444B2 (en) | 2013-12-17 | 2016-11-15 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
WO2015095391A1 (en) | 2013-12-17 | 2015-06-25 | Pharmaceutical Manufacturing Research Services, Inc. | Extruded extended release abuse deterrent pill |
ES2942619T3 (es) | 2014-06-11 | 2023-06-05 | SpecGx LLC | Composiciones secadas por aspersión con diferentes perfiles de disolución y procedimientos para su preparación |
US9707184B2 (en) | 2014-07-17 | 2017-07-18 | Pharmaceutical Manufacturing Research Services, Inc. | Immediate release abuse deterrent liquid fill dosage form |
EP3209282A4 (en) | 2014-10-20 | 2018-05-23 | Pharmaceutical Manufacturing Research Services, Inc. | Extended release abuse deterrent liquid fill dosage form |
US11197830B2 (en) | 2019-02-27 | 2021-12-14 | Aft Pharmaceuticals Limited | Pharmaceutical composition containing acetaminophen and ibuprofen |
CA3201462A1 (en) * | 2020-11-13 | 2022-05-19 | Bayer Healthcare Llc | Oral bilayer tablets comprising acetylsalicylic acid and pseudoephedrine, methods of preparing and using thereof |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB191225486A (en) | 1912-11-06 | 1913-04-24 | Herbert Sefton-Jones | Manufacture and Production of Improved Pharmaceutical Preparations. |
US2293359A (en) | 1941-01-08 | 1942-08-18 | Quisling Sverre | Acetyl salicylic acid preparation |
FI89004C (fi) | 1988-02-16 | 1993-08-10 | Pertti J Neuvonen | Anvaendning av tillsatsmedel foer oekning av absorptionshastigheten av laekemedel i orala laekemedelspreparat |
RU2099058C1 (ru) | 1992-06-15 | 1997-12-20 | Институт химии твердого тела и переработки минерального сырья СО РАН | Способ получения твердой быстрорастворимой дисперсной системы, содержащей ацетилсалициловую кислоту |
US5665388A (en) | 1995-11-13 | 1997-09-09 | Health Corporation | Method for preparation of an alkaline and aspirin combination compound |
KR20010023256A (ko) | 1997-08-27 | 2001-03-26 | 헥살 아게 | 용해도와 생체 이용성이 개선된 신규의 멜록시캄 의약조성물 |
US8231899B2 (en) * | 1998-09-10 | 2012-07-31 | Nycomed Danmark Aps | Quick release pharmaceutical compositions of drug substances |
US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
RU2170582C1 (ru) | 2000-02-17 | 2001-07-20 | Институт химии твердого тела и механохимии СО РАН | Способ получения быстрорастворимой таблетированной формы ацетилсалициловой кислоты |
US20080255104A1 (en) | 2004-05-04 | 2008-10-16 | Equitech Corporation | Nsaid Compositions |
US8216610B2 (en) | 2004-05-28 | 2012-07-10 | Imaginot Pty Ltd. | Oral paracetamol formulations |
EA014443B1 (ru) * | 2004-06-29 | 2010-12-30 | Никомед Данмарк Апс | Фармацевтическая композиция (варианты) и способ ее производства |
CA2584957C (en) * | 2004-10-21 | 2015-08-25 | Eurand Pharmaceuticals Limited | Taste-masked pharmaceutical compositions with gastrosoluble pore-formers |
AU2006317530B2 (en) | 2005-11-28 | 2011-09-01 | Imaginot Pty Ltd | Oral therapeutic compound delivery system |
US11135188B2 (en) | 2009-05-11 | 2021-10-05 | Bayer Healthcare Llc | Method and composition to improve absorption of therapeutic agents |
-
2009
- 2009-05-11 US US12/387,977 patent/US11135188B2/en active Active
-
2010
- 2010-05-10 EP EP10775187.7A patent/EP2429502B1/en active Active
- 2010-05-10 WO PCT/US2010/001375 patent/WO2010132095A1/en active Application Filing
- 2010-05-10 PT PT10775187T patent/PT2429502T/pt unknown
- 2010-05-10 EA EA201171399A patent/EA201171399A1/ru unknown
- 2010-05-10 BR BRPI1013509A patent/BRPI1013509A2/pt not_active IP Right Cessation
- 2010-05-10 HU HUE10775187A patent/HUE043173T2/hu unknown
- 2010-05-10 SI SI201031864T patent/SI2429502T1/sl unknown
- 2010-05-10 MX MX2011011928A patent/MX2011011928A/es unknown
- 2010-05-10 PL PL10775187T patent/PL2429502T3/pl unknown
- 2010-05-10 CA CA2761678A patent/CA2761678A1/en not_active Abandoned
- 2010-05-11 AR ARP100101627A patent/AR076864A1/es unknown
- 2010-05-11 UY UY0001032624A patent/UY32624A/es not_active Application Discontinuation
-
2011
- 2011-11-10 CL CL2011002807A patent/CL2011002807A1/es unknown
- 2011-11-11 CO CO11153958A patent/CO6460753A2/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EA201171399A1 (ru) | 2012-05-30 |
EP2429502A4 (en) | 2012-10-24 |
US20100286100A1 (en) | 2010-11-11 |
PL2429502T3 (pl) | 2019-07-31 |
WO2010132095A8 (en) | 2011-07-07 |
HUE043173T2 (hu) | 2019-08-28 |
CL2011002807A1 (es) | 2012-06-15 |
WO2010132095A1 (en) | 2010-11-18 |
EP2429502A1 (en) | 2012-03-21 |
UY32624A (es) | 2010-12-31 |
US11135188B2 (en) | 2021-10-05 |
SI2429502T1 (sl) | 2019-05-31 |
BRPI1013509A2 (pt) | 2016-04-05 |
EP2429502B1 (en) | 2018-12-26 |
PT2429502T (pt) | 2019-03-29 |
CO6460753A2 (es) | 2012-06-15 |
CA2761678A1 (en) | 2010-11-18 |
AR076864A1 (es) | 2011-07-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2011011928A (es) | Procedimiento y composicion para mejorar la absorcion de agentes terapeuticos. | |
MY147641A (en) | Fast release paracetamol tablets | |
TR201909173T4 (tr) | İşlevselleştirilmiş kalsiyum karbonat içeren hızlı parçalanan katı dozaj formundaki formülasyon ve bunun üretim yöntemi. | |
MY173215A (en) | Acetylcysteine compositions and methods of use thereof | |
PH12017501688A1 (en) | Intranasal benzodiazepine pharmaceutical compositions | |
UA107967C2 (en) | Pharmaceutical composition in the form of bilayer tablets which contain inhibitor of hmg-coa reductase inhibitor and irbesartan | |
MX2010007083A (es) | Combinacion anti-retroviral. | |
NZ595467A (en) | Sublingual pharmaceutical composition comprising a neutral oil | |
EP2515943A4 (en) | MICROCRYSTALLINE CELLULOSE AND CALCIUM CARBONATE COMPOSITIONS USEFUL AS RECOMPACTABLE PHARMACEUTICAL EXCIPIENTS | |
MX2019008817A (es) | Formulacion de liberacion prolongada para reducir la frecuencia de miccion y metodo de uso de la misma. | |
TN2012000507A1 (en) | Enteric tablet | |
IN2015DN03921A (es) | ||
MX2010007281A (es) | Composiciones farmaceuticas de amlodipina y valsartan. | |
MX2015012109A (es) | Composicion farmaceutica oral de sales sulfato para comprimidos de uso dual y metodos para su uso. | |
TR201001417A1 (tr) | Geliştirilmiş çözünme hızına sahip sefdinir formülasyonu | |
PH12015501377A1 (en) | Solid unit with high fexofenadine content and process for the preparation thereof | |
PH12015500395A1 (en) | Pharmaceutical composite capsule formulation comprising irbesartan and hmg-coa reductase inhibitor | |
PE20061390A1 (es) | Formulaciones de acido hidroxamico suberoilanilida y procedimientos para la produccion de las mismas | |
IN2014MN02156A (es) | ||
MX2012001893A (es) | Tableteado de eritritol e isomaltosa. | |
PH12015500394A1 (en) | Bilayered composite tablet formulation comprising atorvastatin, irbesartan and magnesium carbonate | |
IN2014CN04119A (es) | ||
IN2012CH03125A (es) | ||
GEP20115310B (en) | Medicinal preparation of amisulpride in the solid form and the method of its manufacture | |
GR1007316B (el) | Φαρμακευτικη συνθεση δισκιων ανθρακικου ασβεστιου |